Trial Profile
A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 24 Feb 2022
Price :
$35
*
At a glance
- Drugs Erenumab (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Amgen
- 10 Feb 2022 Status changed from recruiting to discontinued. Reason the study was stopped: Per Amgen Regulatory and Study Team, the study can move forward with the close out activities for the PK study since all ongoing subjects have completed based.
- 08 Jun 2021 Planned End Date changed from 28 Dec 2021 to 26 Jun 2022.
- 08 Jun 2021 Planned primary completion date changed from 15 Oct 2021 to 13 Apr 2022.